Solentim and ATUM to bundle Leap-In Transposase® with the VIPS™ single cell cloning instrument for cell line development
Bournemouth, UK and Newark, CA, USA, 20th April 2020 / Sciad Newswire / Solentim, a global leader in cell line development (CLD) instrumentation, and bioengineering company ATUM, today announced that Solentim will bundle access to the Leap-In Transposase® platform together with the Solentim VIPS™ single cell cloning instrument. Leap-In Transposases enable stable high titer clones to be isolated whilst screening orders of magnitude fewer clones than alternative strategies. The VIPS seeding and clonality validation system is optimized to efficiently isolate and track each high expressing clone. This new commercial agreement will enable Solentim’s customers all over the world to readily access the Leap-In Transposase technology.
“This agreement further cements our partnership with ATUM,” explained Dr Ian Taylor, Chief Business Officer of Solentim. “Over the past few months, we have seen pharma customers receive the first IND approvals using Leap-In Transposase, giving confidence to other customers that Leap-In combined with the VIPS technology is a sound choice when implementing their commercial CLD workflow.”
“We have fully embraced the VIPS technology from Solentim within our own company and it has become a cornerstone of our cell line development process. Solentim has been an outstanding partner to work with and we look forward to expanding our commercial success for Leap-In using their strong brand in CLD and global routes to market” commented Dr Jeremy Minshull, CEO of ATUM.
Notes to editors:
VIPS™ from Solentim is a unique All-in-One instrument which performs single cell seeding into 96 well plates, verifying success by z-stack imaging of the nanolitre (nL) volume droplets, and then performing whole well imaging of the single cell for the regulatory requirements for clonally-derived MCB.
About Leap-In Transposase Technology
The Leap-In Transposase® rapidly catalyses the stable integration of genes into a target genome. Genes are integrated as multiple independent copies with structural integrity perfectly maintained. This greatly reduces the screening burden required compared with slower, more traditional "random integration" methods where the introduced DNA is randomly fragmented and often rearranged. ATUM's Leap-In technology is protected by over a dozen pending and issued patents.
Solentim is the global leader in enabling accelerated cell line development for new biologic drugs through its proprietary intelligent automation. Solentim’s portfolio of products (VIPS™, Cell Metric® and Cell Metric® CLD) enables customers to establish a simple to use and completely integrated workflow, revolutionising single cell cloning and providing documented daily whole well image assurance of monoclonality for FDA and other regulatory bodies. Solentim works with most of the world’s top 10 pharmaceutical companies and has a customer installed base of several hundred instruments. In 2018, Solentim was the recipient of two highly prestigious Queen’s Awards and named in the Deloitte UK Technology Fast 50. Visit www.solentim.com for more information.
ATUM offers an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and strain engineering and production. ATUM exploits the dependence of biological activity on well-designed sequences. ATUM’s tools and solutions are fuelling the transformation of biology from a discovery science to an engineering discipline. By collaborating with our clients, ATUM accelerates breakthroughs and moves research further faster.
For further information, contact:
Ian Taylor, CBO
T: +44 (0)1202 051813
Claes Gustafsson, CCO
T: 1 (650) 853 8347
Juliette Craggs/Richard Anderson
Sciad Communications Ltd
T: +44 (0)20 3405 7892